Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality?

被引:215
作者
Adam, Rene [1 ]
Wicherts, Dennis A.
de Haas, Robbert J.
Aloia, Thomas
Levi, Francis
Paule, Bernard
Guettier, Catherine
Kunstlinger, Francis
Delvart, Valerie
Azoulay, Daniel
Castaing, Denis
机构
[1] Hop Paul Brousse, AP HP, Ctr Hepato Biliarire, F-94804 Villejuif, France
关键词
D O I
10.1200/JCO.2007.13.7471
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Complete clinical response ( CCR) of colorectal liver metastases ( CLM) following chemotherapy is of limited predictive value for complete pathologic response ( CPR) and cure of the disease. The objective of this study was to determine predictive factors of CPR as well as its impact on survival. Patients and Methods From January 1985 to July 2006, 767 consecutive patients with CLM underwent liver resection after systemic chemotherapy. Patients with CPR were compared with patients without CPR. Results Twenty-nine of 767 ( 4%) patients had CPR, and none of these 29 patients had CCR. Patients with CPR ( mean age, 54 years) had a mean number of 3.3 metastases at diagnosis ( mean size, 29.3 mm). Objective response and stable disease were observed in 79% and 21% of cases, respectively. Postoperative mortality rate was 0%. After a median follow-up of 52.2 months ( range, 1.1 to 193.0 months), overall 5-year survival was 76% for patients with CPR compared with 45% for patients without CPR ( P = .004). Independent predictive factors for CPR were: age <= 60 years, size of metastases <= 3 cm at diagnosis, carcinoembryonic antigen ( CEA) level at diagnosis <= 30 ng/mL, and objective response following chemotherapy. The probability of CPR ranged from 0.2% when all factors were absent to 30.9% when all were present. Conclusion CPR was observed in 4% of patients with CLM treated with preoperative chemotherapy. However, CPR may occur in almost one-third of objective responders age <= 60 years with metastases <= 3 cm and low CEA values. CPR is associated with uncommon high survival rates.
引用
收藏
页码:1635 / 1641
页数:7
相关论文
共 25 条
  • [11] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) : 337 - 345
  • [12] Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: Results from intergroup N9741
    Dy, Grace K.
    Krook, James E.
    Green, Erin M.
    Sargent, Daniel J.
    Delaunoit, Thierry
    Morton, Roscoe F.
    Fuchs, Charles S.
    Ramanathan, Ramesh K.
    Williamson, Stephen K.
    Findlay, Brian P.
    Pockaj, Barbara A.
    Sticca, Robert P.
    Alberts, Steven R.
    Pitot, Henry C.
    Goldberg, Richard M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3469 - 3474
  • [13] Incidence of unsuspected and treatable metastatic disease associated with operable colorectal liver metastases discovered only at laparotomy (and not treated when performing percutaneous radiofrequency ablation)
    Elias, D
    Sideris, L
    Pocard, M
    de Baere, T
    Dromain, C
    Lassau, N
    Lasser, P
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (04) : 298 - 302
  • [14] Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy
    Elias, D
    Youssef, O
    Sideris, L
    Dromain, C
    Baton, O
    Boige, V
    Ducreux, M
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2004, 86 (01) : 4 - 9
  • [15] Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
    Folprecht, G
    Lutz, MP
    Schöffski, P
    Seufferlein, T
    Nolting, A
    Pollert, P
    Köhne, CH
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (03) : 450 - 456
  • [16] Liver resection for colorectal metastases
    Fong, YM
    Cohen, AM
    Fortner, JG
    Enker, WE
    Turnbull, AD
    Coit, DG
    Marrero, AM
    Prasad, M
    Blumgart, LH
    Brennan, MF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 938 - 946
  • [17] Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
    Giacchetti, S
    Itzhaki, M
    Gruia, G
    Adam, R
    Zidani, R
    Kunstlinger, F
    Brienza, S
    Alafaci, E
    Bertheault-Cvitkovic, F
    Jasmin, C
    Reynes, M
    Bismuth, H
    Misset, JL
    Lévi, F
    [J]. ANNALS OF ONCOLOGY, 1999, 10 (06) : 663 - 669
  • [18] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H
    Fehrenbacher, L
    Novotny, W
    Cartwright, T
    Hainsworth, J
    Heim, W
    Berlin, J
    Baron, A
    Griffing, S
    Holmgren, E
    Ferrara, N
    Fyfe, G
    Rogers, B
    Ross, R
    Kabbinavar, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2335 - 2342
  • [19] Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery
    Rubbia-Brandt, L.
    Giostra, E.
    Brezault, C.
    Roth, A. D.
    Andres, A.
    Audard, V.
    Sartoretti, P.
    Dousset, B.
    Majno, P. E.
    Soubrane, O.
    Chaussade, S.
    Mentha, G.
    Terris, B.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (02) : 299 - 304
  • [20] Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
    Saltz, LB
    Cox, JV
    Blanke, C
    Rosen, LS
    Fehrenbacher, L
    Moore, MJ
    Maroun, JA
    Ackland, SP
    Locker, PK
    Pirotta, N
    Elfring, GL
    Miller, LL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) : 905 - 914